Advertisement
Home 2023

Archives

Bulevirtide Linked to Decline in Hepatitis D Virus RNA Levels

0

Normalization of alanine aminotransferase also seen with bulevirtide 2- or 10-mg

Pegozafermin Leads to Improvements in Fibrosis in NASH

0

Improvements also seen in NASH resolution with pegozafermin 15 or 30 mg weekly, or 44 mg every two weeks

ADA: Childhood Hyperglycemia Linked to Future Microvascular Complications

0

Higher HbA1c, two-hour plasma glucose linked to significantly increased risk of retinopathy in children without T2D

ADA: Reductions in Body Weight With Retatrutide for Obesity

0

Substantial reductions seen in body weight with retatrutide treatment for 48 weeks in phase 2 trial

Review Looks at Psychological Burden of Children, Young Adult Cancer Patients

0

Children, adolescent, and young adult patients with cancer at increased lifetime risk of diagnosis or increased severity of depression, anxiety, and psychotic disorders

ADA: Once-Weekly Icodec Superior for Reduction in HbA1c

0

Noninferior and superior reduction in HbA1c with one-weekly icodec versus once-daily degludec in insulin-naive type 2 diabetes patients

ADA: Once-Daily Semaglutide Superior for Reduction in Body Weight

0

Superior and clinically meaningful reduction in body weight in adults with overweight, obesity without type 2 diabetes

ENDO: Women With Polycystic Ovary Syndrome Experience More Body Image Concerns

0

Authors say findings show need for body image screening in clinical practice

ADA: Once-Weekly Tirzepatide Leads to Weight Loss in Patients With Obesity, T2D

0

Substantial and clinically meaningful reductions in body weight seen for adults with obesity and type 2 diabetes

ADA: Bempedoic Acid Cuts MACE in Statin-Intolerant Patients

0

Significant risk reduction in primary end point of composite of cardiovascular death nonfatal myocardial infarction, nonfatal stroke, coronary revascularization